Bionexus Gene Lab Stock Z Score
| BGLC Stock | USD 0.25 0.04 13.79% |
BioNexus | Z Score |
BioNexus Gene Lab Company Z Score Analysis
BioNexus Gene's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
BioNexus Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for BioNexus Gene is extremely important. It helps to project a fair market value of BioNexus Stock properly, considering its historical fundamentals such as Z Score. Since BioNexus Gene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNexus Gene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNexus Gene's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, BioNexus Gene Lab has a Z Score of 0.0. This is 100.0% lower than that of the Chemicals sector and 100.0% lower than that of the Materials industry. The z score for all United States stocks is 100.0% higher than that of the company.
BioNexus Gene Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioNexus Gene from analyzing BioNexus Gene's financial statements. These drivers represent accounts that assess BioNexus Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNexus Gene's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 35.4M | 236.8M | 364.8M | 164.3M | 8.4M | 8.0M | |
| Enterprise Value | 34.6M | 234.1M | 362.8M | 162.2M | 2.6M | 2.5M |
BioNexus Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 1.32 M | ||||
| Shares Outstanding | 17.97 M | ||||
| Shares Owned By Insiders | 43.72 % | ||||
| Shares Owned By Institutions | 0.87 % | ||||
| Number Of Shares Shorted | 140.38 K | ||||
| Price To Earning | 350.00 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 0.57 X | ||||
| Revenue | 9.77 M | ||||
| Gross Profit | 2.19 M | ||||
| EBITDA | (2.49 M) | ||||
| Net Income | (2.63 M) | ||||
| Cash And Equivalents | 1.34 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 133.4 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 3.84 X | ||||
| Book Value Per Share | 0.55 X | ||||
| Cash Flow From Operations | (1.3 M) | ||||
| Short Ratio | 2.21 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Number Of Employees | 30 | ||||
| Beta | 1.87 | ||||
| Market Capitalization | 5.23 M | ||||
| Total Asset | 11.4 M | ||||
| Retained Earnings | (1.84 M) | ||||
| Working Capital | 6.42 M | ||||
| Net Asset | 11.4 M |
About BioNexus Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNexus Gene Lab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNexus Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNexus Gene Lab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out BioNexus Gene Piotroski F Score and BioNexus Gene Valuation analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.